SILVER SPRING, Md. and CHERTSEY, England, Dec.

SILVER SPRING, Md., June 6, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine (oral treprostinil), an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).

SILVER SPRING, Md., February 2, 2011 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that enrollment in its FREEDOM-M registration trial was completed on January 31, 2011. FREEDOM-M is a 12-week, multi-center, international, double-blind, randomized, placebo-controlled study of a sustained release oral formulation of treprostinil diethanolamine in pulmonary arterial hypertension (PAH)patients not receiving any other approved PAH therapy. The FREEDOM-M study enrolled 349 patients, compared to a target enrollment of 315 patients.

SILVER SPRING, Md., July 1 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) and Lee's Pharmaceutical Holdings Ltd. (HKEx: 0950) announced today that they have entered into an exclusive agreement for the distribution of Remodulin (treprostinil) Injection in China.

SILVER SPRING, Md., Feb.